NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading GENB? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →Intact: The reason to own it still holds.
Generate Biomedicines uses AI to speed drug discovery. Revenue could grow from $6.25M this quarter to about $25.9M in 2026. The company is not loss-making and aims to improve earnings from -$2.24 to -$2.06 per share next year.
The company missed earnings recently and EPS is expected to stay negative at -$2.24 in 2026. Revenue estimates have been revised down by analysts. The business may struggle to reach profitability or grow revenue sustainably.
The market currently prices in continued losses with EPS around -$2.24 in 2026 and modest revenue near $25.9M. Our view is cautious given recent earnings misses and downward estimate revisions.
Breaks if: EPS loss worsens or stays below -$2.24 in FY26
Breaks if: loss of key partnerships or platform setbacks
Breaks if: revenue falls below $25M in FY26
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
